Please assess the completion status of the following clinical trial:

Trial Title: Safety, Tolerability, and Immunogenicity of V114 in Healthy Infants (V114-025)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria~* Healthy~* Has a legally acceptable representative who understands the study procedures, alternate treatments available, and risks involved with the study and voluntarily agrees to participate by giving written informed consent~Exclusion Criteria~* History of invasive pneumococcal disease \[(IPD); positive blood culture, positive cerebrospinal fluid culture, or other sterile site\] or known history of other culture positive pneumococcal disease~* Has a known or suspected impairment of immunological function~* Has a history of congenital or acquired immunodeficiency~* Has, or his/her mother has, a documented human immunodeficiency virus (HIV) infection~* Has, or his/her mother has, a documented hepatitis B surface antigen - positive test~* Has known or history of functional or anatomic asplenia~* Has failure to thrive based on the clinical judgement of the Investigator~* Has a bleeding disorder contraindicating intramuscular vaccination~* Has a history of autoimmune disease (including but not limited to systemic lupus erythematosus, antiphospholipid syndrome, Behcet's disease, autoimmune thyroid disease, polymyositis and dermatomyositis, scleroderma, Type 1 diabetes mellitus, or other autoimmune disorders)~* Has a known neurologic or cognitive behavioral disorder, including encephalitis/myelitis, acute disseminating encephalomyelitis, pervasive development disorder, and related disorders~* Has received a dose of any pneumococcal vaccine prior to study entry~* Has received \>1 dose of monovalent hepatitis B vaccine or hepatitis B-based combination vaccine prior to study entry~* Has received a dose of any acellular pertussis- or whole cell pertussis-based combination vaccines, Haemophilus influenzae type b conjugate vaccine, poliovirus vaccine, rotavirus vaccine, or any other combination thereof, prior to study entry~* Has received a blood transfusion or blood products, including immunoglobulins~* Has participated in another clinical study of an investigational product before the beginning or anytime during the duration of the current clinical study. Participants enrolled in observational studies may be included; these will be reviewed on a case-by-case basis for approval by the Sponsor~* Is or has an immediate family member (eg, parent/legal guardian or sibling) who is investigational site or Sponsor staff directly involved with this study

- Gender: ALL
- Minimum Age: 42 Days
- Maximum Age: 90 Days
- Healthy Volunteers: t

Study Arms:
- V114 (Type: EXPERIMENTAL): Full-term infants received a 0.5 mL intramuscular injection of V114 at approximately 2, 4, and 11-15 months of age (Study Day 1, Month 2, and Month 9-13). Preterm infants received a 0.5 mL intramuscular injection of V114 at approximately 2, 3, 4, and 11-15 months of age (Study Day 1, Month 1, Month 2, and Month 9-13). All infants also received intramuscular injection of 0.5 mL Infanrix™ hexa at approximately 2, 3, 4, and 11-15 months of age and 1.5 mL oral dose of Rotarix™ at 2 and 4 months of age.
- Prevenar 13™ (Type: ACTIVE_COMPARATOR): Full-term infants received a 0.5 mL intramuscular injection of Prevenar 13™ at approximately 2, 4, and 11-15 months of age (Study Day 1, Month 2, and Month 9-13). Preterm infants received a 0.5 mL intramuscular injection of Prevenar 13™ at approximately 2, 3, 4, and 11-15 months of age (Study Day 1, Month 1, Month 2, and Month 9-13). All infants also received intramuscular injection of 0.5 mL Infanrix™ hexa at approximately 2, 3, 4, and 11-15 months of age and 1.5 mL oral dose of Rotarix™ at 2 and 4 months of age.

Based on this trial design, predict the completion outcome and termination type (if applicable).